| BCBS Federal Medical & Drug | 2.04.68 Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients with Cancer | 2025-06-01 |
| BCBS Federal Medical & Drug | 2.04.86 Genetic Testing for Duchenne and Becker Muscular Dystrophy | 2025-06-01 |
| BCBS Federal Medical & Drug | 2.04.87 Genetic Testing for Hereditary Hearing Loss | 2025-06-01 |
| BCBS Federal Medical & Drug | 2.04.88 Genetic Testing for PTEN Hamartoma Tumor Syndrome | 2025-06-01 |
| BCBS Federal Medical & Drug | 2.04.99 Genetic Testing for Hereditary Pancreatitis | 2025-06-01 |
| BCBS Federal Medical & Drug | 2.04.103 Genetic Testing for Macular Degeneration | 2025-06-01 |
| BCBS Federal Medical & Drug | 2.04.109 Genetic Testing for Epilepsy | 2025-06-01 |
| BCBS Federal Medical & Drug | 2.04.114 Genetic Testing for Idiopathic Dilated Cardiomyopathy | 2025-06-01 |
| BCBS Federal Medical & Drug | 2.04.129 Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related Disorders | 2025-06-01 |
| BCBS Federal Medical & Drug | 2.04.148 Germline Genetic Testing for Pancreatic Cancer Susceptibility Genes (ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53) | 2025-06-01 |